The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.
The cancers can be ordered histologically or alphabetically.
For each cancer, the staining for each available antibody is reported as the fraction of samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right). The lenght of the bar represents the number of patient samples analysed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.
At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the immunohistochemistry validation score for that antibody.
Many tumors showed cytoplasmic and membranous immunoreactivity. Strongest staining was observed in renal cancers, prostate cancers and malignant lymphomas.
Most malignant tissues were negative. Rare cases of squamous cell carcinoma, liver cancer and breast cancer showed moderate to strong cytoplasmic and membranous immunoreactivity.
Most malignant cells displayed moderate to strong cytoplasmic and membranous immunoreactivity. A majority of basal cell carcinomas, testicular, endometrial, prostate, breast and colorectal cancers were weakly stained or negative.
Validation
Two (or more) antibodies yielding similar staining patterns which are consistent with available gene/protein characterization data
Two (or more) antibodies yielding similar staining patterns which are consistent with available gene/protein characterization data
Two (or more) antibodies yielding similar staining patterns which are consistent with available gene/protein characterization data
